Annual report pursuant to Section 13 and 15(d)

Statements of Stockholders??? Equity (Deficit)

v3.21.2
Statements of Stockholders’ Equity (Deficit) - USD ($)
Series A Preferred Stock
Series B Preferred Stock
Series C Preferred Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Mar. 31, 2019 $ 329 $ 3,449,516 $ (6,844,488) $ (3,394,643)
Balance (in Shares) at Mar. 31, 2019       3,291,667      
Stock-based compensation $ 200 4,495,969 4,496,169
Stock-based compensation (in Shares)       2,000,000      
Issuance of common stock and warrants in connection with cancellation of consulting agreement $ 3 264,517 264,520
Issuance of common stock and warrants in connection with cancellation of consulting agreement (in Shares)       33,333      
Issuance of common stock in connection with a consulting agreement $ 16 354,984 355,000
Issuance of common stock in connection with a consulting agreement (in Shares)       157,778      
Issuance of common stock in connection with notes payable $ 29 662,221 662,250
Issuance of common stock in connection with notes payable (in Shares)       292,000      
Beneficial conversion feature in connection with notes payable 260,078 260,078
Net loss (9,603,871) (9,603,871)
Balance at Mar. 31, 2020 $ 577 9,487,285 (16,448,359) (6,960,497)
Balance (in Shares) at Mar. 31, 2020       5,774,778      
Stock-based compensation $ 237 14,125,760 14,125,997
Stock-based compensation (in Shares)       2,371,428      
Stock option exercise $ 2 (2)
Stock option exercise (in Shares)       25,000      
Canceled restricted stock awards $ (206) 206
Canceled restricted stock awards (in Shares)       (2,060,000)      
Common stock repurchased and subsequently canceled $ (17) (449,983) (450,000)
Common stock repurchased and subsequently canceled (in Shares)       (166,667)      
Reclassification of warrant liabilities         5,626,891   5,626,891
Issuance of common stock and warrants, net of fees $ 524 20,389,369 20,389,893
Issuance of common stock and warrants, net of fees (in Shares)       5,235,833      
Issuance of common stock in satisfaction of accounts payable       $ 6 121,829   121,835
Issuance of common stock in satisfaction of accounts payable (in Shares)       54,149      
Issuance of common stock in connection with notes payable $ 37 1,133,613 1,133,650
Issuance of common stock in connection with notes payable (in Shares)       366,667      
Issuance of common stock and preferred stock in connection with conversion of notes 50 $ 283 23,715,494 23,715,827
Issuance of common stock and preferred stock in connection with conversion of notes, (in Shares) 251 1,443 500,756 2,830,079      
Repurchased beneficial conversion feature in connection with conversion of notes payable (6,646,998) (6,646,998)
Issuance of common stock warrants in connection with note exchange agreements         4,918,172   4,918,172
Issuance of common stock warrants 263,328 263,328
Exercise of common stock warrants $ 32 179,952 179,984
Exercise of common stock warrants (in Shares)       316,421      
Beneficial conversion feature in connection with notes payable 618,657 618,657
Issuance of common stock to consultants $ 11 305,424 305,435
Issuance of common stock to consultants (in Shares)       108,792      
Net loss (40,755,125) (40,755,125)
Balance at Mar. 31, 2021 $ 50 $ 1,486 $ 73,788,997 $ (57,203,484) $ 16,587,049
Balance (in Shares) at Mar. 31, 2021 251 1,443 500,756 14,856,480     375,000